Amneal reprices $2.084B term loan, cuts interest margin by 50 bps, saving ~$12M annually

Amneal Pharmaceuticals, Inc.

Reduced interest rate margin by 50 bps to 1.50% (base rate) and 2.50% (SOFR) on $2.084B term loans.
Converted $2.039B existing term loans on cashless basis; added $45.2M new term loan to repay non-converted loans.
Maturity unchanged at August 1, 2032; no prepayment premium for repricing after February 3, 2027.
Estimated annualized cash interest savings of approximately $12 million based on outstanding borrowings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.